Moderna Secures FDA Approval for RSV Vaccine

The FDA has approved Moderna’s mRESVIA to shield individuals 60 years of age and above from infections of the lower respiratory tract brought on by respiratory syncytial virus (RSV) infection. The good will be released by the corporation in time for the 2024–2025 RSV period, which normally begins in the United States in the late autumn.

After 3.7 months of average check-up, Moderna’s vaccine was linked to an 83.7% effectiveness rate against RSV-associated lower respiratory tract illness in a major phase 3 study including 22 nations.

The vaccines from Moderna, Pfizer, and GSK have all received FDA clearance for usage among older individuals, and Pfizer’s product may be utilised as well as a mother immunisation to protect her unborn child.

Moderna is exploring mRNA options against influenza, HIV, Lyme disease, and numerous other illnesses in addition to COVID-19 and RSV.